𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Summary of guideline for the treatment of depression

✍ Scribed by Pete M. Ellis; Ian B. Hickie; Don A. R. Smith


Publisher
Informa plc
Year
2003
Tongue
English
Weight
120 KB
Volume
11
Category
Article
ISSN
1039-8562

No coin nor oath required. For personal study only.

✦ Synopsis


Depression is common, serious and treatable. The Australian and New Zealand Clinical Practice Guideline for the Treatment of Depression by Specialist Services provides evidence-based treatment guidance across the spectrum of depressive disorders and delineates where specialist treatment and primary care management is indicated. The present summary version covers the key contents of the guideline. It includes assessment, treatment and general management issues by category type and severity of depressive disorder. Algorithms of first-line and subsequent treatment choices are provided for: (i) mild depression without complications; (ii) moderately severe depression (including with comorbid anxiety) and dysthymia; (iii) uncomplicated, melancholic or atypical depression; (iv) moderately severe depression with comorbid substance abuse; (v) moderate to severe depression with physical disorders; (vi) severe depression with melancholia; (vii) recurrent depression or failure to respond to a preferred first-line treatment; and (viii) psychotic depression, and severe depression with risk of suicide. Continuing and maintenance treatments for recurrent depression are discussed. Emerging evidence of the equal value of cognitive behaviour therapy (CBT) and interpersonal psychotherapy (IPT) to pharmacological treatments for some depression is discussed, and the need to ensure that they are provided by suitably trained practitioners. Indications for hospitalization and electroconvulsive therapy (ECT) are also provided.


πŸ“œ SIMILAR VOLUMES


Summary of guideline for the treatment o
✍ Philip B. Mitchell; Gin S. Malhi; Bernette L. Redwood; Jillian Ball πŸ“‚ Article πŸ“… 2003 πŸ› Informa plc 🌐 English βš– 182 KB

The past decade has witnessed an extraordinary expansion of treatments available for bipolar disorder. Ten years ago, lithium was the only approved agent for this condition. Since that time, carbamazepine, valproate and olanzapine have received regulatory approval for the acute treatment of mania. C

Summary of guideline for the treatment o
✍ Gavin Andrews; Mark Oakley-Browne; David Castle; Fiona Judd; Andrew Baillie πŸ“‚ Article πŸ“… 2003 πŸ› Informa plc 🌐 English βš– 119 KB

Objective: To provide a summary of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Clinical Practice Guideline for the treatment of panic disorder and agoraphobia Conclusions: Evidence-based treatments for panic disorder and agoraphobia are now clear. These conditions are c

Prenatal Depression: Best Practice Guide
✍ Laura H. Choate; Gary G. Gintner πŸ“‚ Article πŸ“… 2011 πŸ› American Counseling Association 🌐 English βš– 111 KB

Depression is a chronic and recurrent condition that is one of the leading causes of disability for women globally (Murray & Lopez, 1997). Women are two to three times more likely to have depression compared with men, with peak prevalence rates occurring during a woman's child-bearing years (America

Guideline for the management of late-lif
✍ Robert C. Baldwin; David Anderson; Sarah Black; Sandra Evans; Rob Jones; Ken Wil πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 101 KB πŸ‘ 1 views

## Abstract ## Objective To develop a guideline for the primary care management of depression in later life based on best practice. ## Method Source material included relevant guidelines, literature reviews and consensus documents coupled with an updated literature review covering 1998–October,

Strategies for the rapid treatment of de
✍ Frederick E. Miller πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 1 views

The purpose of this article is to review current literature relating to the determination of the time course of antidepressant effects. Further, this work explores studies examining the safety and effectiveness of pharmacological techniques for accelerating the therapeutic effects of antidepressant